Published in Int J Cancer on August 24, 2011
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine (2014) 1.07
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (Basel) (2015) 0.87
Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology (2013) 0.82
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int (2013) 0.80
A molecular profile of T-cell exhaustion in cancer. Oncoimmunology (2012) 0.79
Engineered Materials for Cancer Immunotherapy. Nano Today (2015) 0.78
Adjuvants for peptide-based cancer vaccines. J Immunother Cancer (2016) 0.75
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. Front Immunol (2016) 0.75
IL-10: Expanding the Immune Oncology Horizon. Receptors Clin Investig (2015) 0.75
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology (2016) 0.75
Cancer immunotherapy drives implementation science in oncology. Hum Vaccin Immunother (2014) 0.75
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol (2008) 2.87
SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem (2011) 2.74
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res (2011) 2.46
Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum (2005) 2.42
Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol (2004) 2.40
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers. EMBO J (2009) 2.20
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem (2007) 1.89
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity (2006) 1.72
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood (2012) 1.65
Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer (2002) 1.60
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun (2006) 1.58
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta (2007) 1.50
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension (2011) 1.46
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days? Acta Oncol (2006) 1.43
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab (2003) 1.41
A cost-effective algorithm for hereditary nonpolyposis colorectal cancer detection. Am J Clin Pathol (2006) 1.40
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol (2010) 1.40
The three main stumbling blocks for anticancer T cells. Trends Immunol (2012) 1.38
CD8 kinetically promotes ligand binding to the T-cell antigen receptor. Biophys J (2005) 1.38
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
A constant affinity threshold for T cell tolerance. J Exp Med (2007) 1.36
Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis (2010) 1.35
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
Structural prediction of peptides bound to MHC class I. J Mol Biol (2005) 1.33
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol (2013) 1.31
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol (2006) 1.28
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother (2004) 1.27
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest (2004) 1.26
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med (2002) 1.25
Fast docking using the CHARMM force field with EADock DSS. J Comput Chem (2011) 1.25
Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins (2007) 1.25
Model structure of human APOBEC3G. PLoS One (2007) 1.24
Interactions of Ly49 family receptors with MHC class I ligands in trans and cis. J Immunol (2007) 1.24
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Cancer Res (2013) 1.22
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination. EMBO J (2012) 1.21
CD3 delta establishes a functional link between the T cell receptor and CD8. J Biol Chem (2002) 1.20